#genetic testing

Will Leqembi’s primary benefit—a slight slowing of decline in cognition and functioning—make a difference to patients and family members...

Treating cancers with an unknown primary site is challenging because most drugs are approved for specific malignancies.

Learn more about melanoma risk factors, hereditary melanoma, and genetic testing.

Inherited genetic determinants can cause normal variations in PSA levels even in the absence of prostate cancer

Part 2 in a series from the University of Colorado that unpacks the goals of the National Cancer Institute’s National Cancer Plan.

Researchers found a new way to detect cancer risk by looking for a signal in the blood, not for the presence of BRCA gene mutations.

More than a third of people with predisposition genes for breast, ovarian or colon cancer would not have qualified for genetic screening.

Genomic profiling showed patients with African ancestry had fewer actionable mutations and were less likely to qualify for immunotherapy.

Including people in Africa and with African ancestry in studies on inherited genetics to address disparities in prostate cancer outcomes.

Individuals would better understand their personal cancer risks for multiple cancers, make informed decisions

A small group of adults in remission had persisting mutations that predicted their risk of death from having the cancer return.

Immunotherapy and … nothing else? Studies test a potential paradigm shift in treatment for some people with early stage cancers.

Some people have inherited genetic syndromes that increase their risk for colon cancer.

Drugs developed to target particular genetic changes may not be right for every person whose cancer shows those alterations or mutations.

Study finds that risk of adverse side effects from cancer immunotherapy is higher in patients with certain inherited genetic variations.

Rezlidhia (olutasidenib) is approved as a targeted treatment option for adults whose acute myeloid leukemia carries the IDH1 mutation.